StockCode
688506
Investors
中文
|
EN
About Biokin
Founder
Innovative Pharmaceutical Company Synchronizing R&D,
Production and Marketing
Innovation Being Widely Recognized
Enterprise Development Planning
Company Culture
Innovation and R&D
Innovative and Efficient R&D system
SystImmune
Baili-Bio/Baili Pharmaceutical
Clinical Dynamics
Manufacturing and Quality Control
Manufacturing System
GMP standard and quality assurance
Product and Marketing
Comprehensive Marketing System
Anesthesia
Parenteral Nutrition
Anti-infectives
Pediatrics
Traditional Chinese Medicines
Investor Relations
Social Responsibility
Earthquake Relief
Caring Donation
Paying Taxes in Accordance with Law
Charity and Public Welfare
Career Development
Talent Recruitment
Join Us
Pharmacovigilance
Contact
EngLish
中文简体
EngLish
中文简体
English
About Biokin
Innovation and R&D
Manufacturing and Quality Control
Product and Marketing
Investor Relations
Social Responsibility
Career Development
Pharmacovigilance
Contact
NEWS RELEASES
2025
01-13
Notice on the revision of the instructions of Ribavirin Granules
01-04
Biokin Pharmaceutical:Study and implement the spirit of Central Economic Work Conference for high-quality development of the listed company
2024
11-15
Biokin Pharmaceutical Named to Forbes China's 2024 Top 50 Most Innovative Companies
11-15
Biokin Pharmaceutical Recognized as One of 2024 Top 100 Chinese Pharmaceutical Innovative Enterprises and Ranking Top 5 in Innovation Technology Category
09-19
BL-B01D1 Debuts at China's CIFTIS and Is Selected for the Achievement Exhibition
08-05
Great News! Baili Pharma Approved to Establish a National Postdoctoral Research Workstation
05-23
SystImmune, a wholly-owned subsidiary of Biokin Pharmaceutical, appoints Dr. Jonathan Cheng as the new Chief Medical Officer
04-30
Innovation Pioneer: Biokin Pharmaceutical Wins the Title of "ADC Innovation Pioneer Enterprise"
04-19
Biokin Pharmaceutical: BL-B01D1 has been included in the list of breakthrough therapy drugs
03-11
Biokin Pharmaceutical has successfully completed the initial payment of USD 800 million under the development and commercialization license agreement with Bristol Myers Squibb for BL-B01D1
02-19
Baili Pharma Honored as Advanced Collective of Building a Strong Manufacturing City Work of Chengdu 2023
01-01
A New Year’s Message from the Chairman for 2024—Forge ahead on Tortuous Path Ahead
2023
12-12
SystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
11-23
Biokin Pharmaceutical | Awarded the Best Industrial Enterprise in China National Pharmaceutical R&D Product Line
11-14
Biokin Pharmaceutical: Propofol Emulsion Injection to be Selected for the Ninth Batch of National Drug Centralized Procurement
09-25
Guorui Pharmaceutical, a Subsidiary of Biokin Pharmaceutical, won the Sichuan Patent Award
05-04
The World’s Leading Oncologists Joined the Clinical Science Advisory Council of SystImmune, a North American Subsidiary of Biokin Pharmaceutical
05-04
ASCO 2023|Presentation of Results of Five Biokin Pharmaceutical Clinical Studies
03-10
SI-B001（EGFR x HER3）Initiating Phase III Clinical Trial
02-02
2023 New Year’s Speech by the President: “One Step a Footprint, One Step a Realm, Be the Peak of the High Mountain”
01-09
Biokin Pharmaceutical Being Formally Listed on Science and Technology Innovation Board of Shanghai Stock Exchange
01-08
Professor Zhangli: Preliminary Data of Clinical Trial of EGFR×HER3 Bispecific Antibody ADC Drug is Encouraging, Precise Treatment of Lung Caner being Furthered Improved
01-08
Professor Zhang Jian: EGFR×HER3 Bispecific Antibody ADC Drug Aiming At Solveing The Hard Problem of HER2 Drug Resistance, Shows Satisfactory Curative Effects In Preliminary Clinical Data!
01-07
Professor Li Wenbin：The First Clinical Study on GBM by Tetra-specific Antibody Drug Immunotherapy May Change the Survival Situation of the Patients alive with tumour
01-06
Exclusive Interview of Professor Shen Lin｜With Bispecific Antibody ADC Drugs Emerging, Therapy of Gastrointestinal Tumors Going with Double Pace
2022
11-08
Named Exemplar IP Generating Entity on November 08, 2022
11-07
Received provincial certification as the “Technological Innovation Exemplar Entity”
07-01
Received full drug approval on June 28, 2022, for Anbeixin®Enalapril Maleate Oral Solution .
04-28
Launched “Baili Against the Pandemic, Part II” to support the anti-pandemic efforts on April 28, 2022.
02-25
Certified as a “National Enterprise Technology Center” on February 25, 2022
02-11
The First “TCM Culture and Tonifying Qi Festival” Being About to be Held with Great Ceremony
02-11
On February 11, 2022, SystImmune, Inc. named Doctor Martín Sebastian Olivo as its Chief Medical Officer
01-27
Biokin Pharmaceutical Being Ranked in the List of "Top 100 Enterprises for Technological Innovation and Development Capability in Sichuan in 2021”
01-14
Chairman Zhu Yi Being Selected for Tianfu Entrepreneurship Leading Talents Project in “Tianfu Qingcheng Program” in 2021
BACK
SystImmune
Baili Pharmaceutical
Guorui Pharmaceutical
Baili-Bio
Jingxi Pharmaceutical
Hiatt Technology
Company Address：1#, Building 1,No.161, Baili Road, Cross-Strait Science and Technology Industrial Development Park, Wenjiang District, Chengdu City
Postcode：610041
Tel：028-85183639
Sichuan Biokin Pharmaceutical Co.,Ltd Copyright © 2018 All rights reserved
SICPB No. 17035664-1
Internet Drug Information Service Qualification Certificate S/N: (C)-FJYX-2022-0343
CGWAB No.51011502000517
